Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Neuroendocrine Carcinoma

NCT07458906 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Xiamen University as lead sponsor.

NCT NCT07458906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07458906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Neuroendocrine Carcinoma
Lead sponsor
The First Affiliated Hospital of Xiamen University
Phase
Not applicable
Overall status
Recruiting
Start date
March 10, 2026
Completion date
December 31, 2026
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dll3-expressing tumors, neuroendocrine cancer, pet / ct